5d) The most commonly chemotherapy regimen is bendamustine + rituximab (BR), as data from #StiL and #BRIGHT trials showed improved PFS vs. R-CHOP. See https://t.co/ozsOgcqRRn and 🔓 https://t.co/zFfj9vz2FY
514 followers
514 followers
9) Contemporary therapy for #MCL typically involves administration of rituximab with chemotherapy such as #bendamustine (BR) which was shown to outperform R-CHOP in the #StiL Trial. https://t.co/ozsOgcqRRn
2,488 followers
3,295 followers
I've read the StiL trial (BR vs RCHOP in indolent B-NHL) several times during my training, but I'm finding new nuggets while preparing to supervise intern JC when this paper will be discussed. https://t.co/FmKktED7HD 1/🧵